Analysis in clinical application and adverse reactions of immunocheckpoint inhibitors in 55 patients with tumors

Objective To understand the clinical application and adverse reactions of programmed death receptor 1 (PD-1) inhibitors in patients in the Department of Oncology in authors' hospital.

Methods The clinical materials of patients using PD-1 inhibitors in the Department of Oncology in authors' hospital from January 2020 to December 2021 were retrospectively collected, and the general information, medication orders, combined therapeutic plans, imaging evaluation results and adverse reactions of patients were analyzed.

Results Of the 55 patients, there were 33 males and 22 females, with an average age of (63.26±11.23) years and 241 times of PD-1 inhibitors in total; pathological diagnosis mainly included 27 cases of lung cancer (49.09%), 10 cases of liver cancer (18.18%), 3 cases of esophageal cancer (5.45%) and 3 cases of cervical cancer (5.45%); the most commonly used anti-tumor programs were chemotherapy combined with immunotherapy, immunotherapy, and targeted therapy combined with immunotherapy; the frequently used regimens were 200 mg sintilimab for once every three weeks and 200 mg camrelizumab for once every three weeks or once every two weeks; 44 patients had adverse drug reactions, and the most common types were autoimmune diseases (34.54%), bone marrow suppression (20.00%) and general fatigue (10.91%).

Conclusion The application of PD-1 inhibitors in the Department of Oncology in the authors' hospital is still at the exploratory stage, and clinical pharmacists should actively cooperate with clinician to do a good job in pharmaceutical care.